Live oral auxotrophic Shigella flexneri SFL124 vaccine with a deleted aroD gene: characterization and monkey protection studies.

Shigella flexneri SFL124, with a deletion encompassing all, or nearly all, of the coding sequence of gene aroD was obtained after selection on a fusaric acid medium supplemented with 2,3-dihydroxybenzoic acid for tetracycline-sensitive mutants of S. flexneri SFL114 which is an aroD::Tn10 transductant. Two of 20 tetracycline-sensitive mutants tested in colony hybridization with a 32P-labelled DNA probe of approximately 1400 base pairs (comprising all except the 75 N-terminal base pairs of the coding region of gene aroD) did not hybridize. The selected mutant SFL124 is Congo-red positive, invades and shows a limited multiplication in HeLa cells and does not cause keratoconjunctivitis in guinea-pigs. It is well tolerated by Macaca fascicularis monkeys, is excreted for up to 4 days, elicits a slight inflammatory reaction in the colonic mucosa, stimulates significant secretory IgA responses in the intestine and serum IgA and IgG responses against the S. flexneri cell envelope lipopolysaccharide. The immune response conferred a complete protection against challenge with 1 x 10(11) (equivalent to a 100 LD50 dose) live S. flexneri SFL1.     

Vaccination route, infectivity and thioglycollate broth administration: effects on live vaccine efficacy of auxotrophic derivatives of Salmonella choleraesuis

An aromatic-dependent, therefore non-virulent, derivative of a mouse-virulent strain of Salmonella choleraesuis previously shown not to be effective as a live vaccine when given intraperitoneally (i.p.) to Itys mice, was administered to BALB/c mice. Two doses given i.p. or by feeding did not protect against i.p. or oral challenge with 50 to 5000 LD50 of the virulent ancestor strain. By contrast two doses given intravenously (i.v.) gave almost complete protection against i.p. or oral challenge with 500 LD50 and some protection against larger doses. The number of live bacteria (cfu) in the liver and spleen 24 h after administration of the live vaccine was less than 1% of the number inoculated i.p., but c. 25% of the number injected i.v. The number of cfu in the gut 24 h after oral vaccine administration was only c 10(-5) of the number fed. Administration of thioglycollate broth i.p. 5 days before i.p. vaccination increased recovery of live vaccine cfu in the liver and spleen and its protective efficacy. In each case the live vaccine did not multiply extensively in vivo. We have previously shown that a purine- and a thymine-requiring derivative of S. choleraesuis were each considerably attenuated but unlike the aro derivative were effective as i.p. live vaccines in mice. Doses of these strains (c. 10(4) cfu) found protective were administered i.p. to BALB/c mice. Each strain multiplied extensively in the liver and spleen to c. 10(7) cfu by day 6. All these results are in agreement with a correlation of protective efficacy of a live vaccine with the persistence of a large number of the vaccine bacteria in the liver and spleen for several days.     

Echocardiography detection of intracavitary ventricular tumors

Intracavitary ventricular tumors were found in 3 male patients (newborn, and 18 and 23 years old) by 2-D echocardiography (metastasis of an osteogenic sarcoma in the right ventricle, teratoma embryonale growing from the retroperitoneum into the right ventricle, rhabdomyoma of the left ventricle). They all showed a uniform echo pattern and two of them were pedunculated. Wall motility, valves and cardiac dimensions were normal. In each case diagnosis was confirmed intraoperatively or at autopsy. Clinically the metastasis of the osteogenic sarcoma presented as obstruction of the superior vena cava, whereas the teratoma embryonale imitated tricuspid valve disease. The rhabdomyoma caused a systolic murmur and severe postpartal sinus bradycardia. It was successfully removed on the basis of echocardiography alone. 2-D echocardiography is a reliable, noninvasive diagnostic tool for evaluation of intracavitary, ventricular tumors.